PDLIM2: PDZ and LIM Domain 2
A key regulator of NF-κB signaling and tumor suppression
Gene Information Card
| Symbol | PDLIM2 |
|---|---|
| Full Name | PDZ and LIM Domain 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 8p21.3 |
| NCBI Gene ID | 64236 ncbi.nlm.nih.gov/gene/64236 |
| Ensembl ID | ENSG00000120949 |
| UniProt ID | Q96JY6 |
| OMIM ID | 609722 |
| HGNC ID | 20760 |
| Aliases | SLIM, Mystique, FLJ32731 |
Description
PDLIM2 encodes a protein containing a PDZ domain and a LIM domain. It functions as an adaptor protein that targets the p65 subunit of NF-κB for ubiquitination and proteasomal degradation, thereby negatively regulating NF-κB signaling. PDLIM2 also plays roles in cytoskeletal organization, cell adhesion, and tumor suppression. Loss or downregulation of PDLIM2 is associated with various cancers and inflammatory diseases.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Loss of PDLIM2 leads to persistent NF-κB activation, promoting tumor growth and metastasis | PMID: 20010870 |
| Colorectal cancer | Reduced PDLIM2 expression correlates with poor prognosis and increased NF-κB activity | PMID: 23104886 |
| Lung cancer | PDLIM2 silencing via promoter methylation contributes to oncogenesis | PMID: 22198284 |
| Multiple myeloma | PDLIM2 downregulation enhances NF-κB survival signals in myeloma cells | PMID: 19549906 |
| Inflammatory bowel disease | PDLIM2 deficiency exacerbates intestinal inflammation via NF-κB dysregulation | PMID: 26912519 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lymph node | 12.5 | Medium |
| Spleen | 10.8 | Medium |
| Bone marrow | 8.2 | Medium |
| Lung | 6.1 | Low |
| Breast | 4.3 | Low |
| Colon | 3.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 15.2 | Embryonic kidney, high expression |
| HeLa | 9.8 | Cervical cancer, moderate |
| MCF7 | 6.5 | Breast cancer, low |
| A549 | 5.1 | Lung cancer, low |
| Jurkat | 18.7 | T-cell leukemia, high |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.325C>T (p.Arg109*) | Nonsense | <0.1% | Truncation, loss of function |
| c.487G>A (p.Gly163Arg) | Missense | <0.1% | Unknown significance |
| c.631_632del (p.Leu211fs) | Frameshift | <0.1% | Loss of function |
Mutation functional classification
Loss of Function (LOF)
Nonsense and frameshift mutations (e.g., p.Arg109*, p.Leu211fs) result in truncated or unstable protein, impairing NF-κB degradation.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
Pathways
• NF-kappa B signaling pathway (KEGG: hsa04064)
• TNF signaling pathway (KEGG: hsa04668)
• Toll-like receptor signaling pathway (KEGG: hsa04620)
Protein Summary
PDLIM2 is a 351-amino acid protein with an N-terminal PDZ domain and a C-terminal LIM domain. The PDZ domain mediates interactions with target proteins, while the LIM domain is involved in zinc binding and protein-protein interactions. PDLIM2 localizes to the cytoplasm and nucleus, where it acts as an E3 ubiquitin ligase adaptor, targeting the p65 subunit of NF-κB for degradation. This activity is critical for terminating NF-κB signaling and preventing chronic inflammation and tumorigenesis. PDLIM2 also interacts with cytoskeletal components, influencing cell shape and adhesion.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PDLIM2 Knockout HEK293 Cell Line | EDJ-KQ14715 | Human | 64236 | Details Get a Quote |
| PDLIM2 Knockout HCT 116 Cell Line | EDJ-KQ43816 | Human | 64236 | Details Get a Quote |
| PDLIM2 Knockout A-549 Cell Line | EDJ-KQ45037 | Human | 64236 | Details Get a Quote |
| PDLIM2 Knockout HeLa Cell Line | EDJ-KQ45038 | Human | 64236 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
